Zdeněk Linke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zdeněk Linke has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ana Ruiz-Casado
Hospital Universitario Puerta de Hierro Majadahonda
1 shared publication - Eduardo Polo Marques
Medical Oncology Department, Hospital Miguel Servet, Saragossa, Spain
1 shared publication - Ian Chau
Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
1 shared publication - Marina Celanovic
Sanofi, Cambridge, MA 02139, USA
1 shared publication - Marwan Fakih
City of Hope National Medical Center, Duarte, CA
1 shared publication - Pascaline Picard
Ividata, 92300 Levallois Perret, France
1 shared publication
Latest Publications
- Open Access
- 5 October 2023
- Published by Solen s.r.o. in Onkologie
- Vol. 17 (4) , 233-240
Options and rationale for reinstituting anti-EGFR therapy in pretreated RAS wild-type advanced colorectal carcinomas
Selh?n? anti-EGFR l??by u pokro?il?ch RAS wild kolorekt?ln?ch karcinom? v inici?ln?ch lini?ch l??by nemus? zdaleka znamenat jej? trvalou a definitivn? neefektivitu. Mo?nost? je znovunasazen? anti-EGFR l??by po p?edchoz? progresi (rechallenge)....
- 5 October 2023
- Published by Solen s.r.o. in Onkologie
- Vol. 17 (4) , 233-240
Open AccessOptions and rationale for reinstituting anti-EGFR therapy in pretreated RAS wild-type advanced colorectal carcinomas
Selh?n? anti-EGFR l??by u pokro?il?ch RAS wild kolorekt?ln?ch karcinom? v inici?ln?ch lini?ch l??by nemus? zdaleka znamenat jej? trvalou a definitivn? neefektivitu. Mo?nost? je znovunasazen? anti-EGFR l??by po p?edchoz? progresi (rechallenge)....
- Open Access
Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study
For patients with metastatic colorectal cancer (mCRC) that have failed a first-line oxaliplatin-based regimen, the preferred treatment option is an irinotecan-based regimen. This prospective, observational, noncomparative, post-authorization safety study (OZONE) evaluated the safety and effectiveness of aflibercept plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) in patients with mCRC treated in daily practice after failure of an oxaliplatin-based regimen. Patients were grouped by age, renal impairment, hepatic impairment, race, number, and type of prior anticancer therapy. Of 766 treated patients enrolled, 59.5% were male, 94.8% had an Eastern Cooperative Oncology Group performance status of 0–1, all received previous chemotherapy (97.8% including oxaliplatin), and 58.6% had prior exposure to bevacizumab. At least one grade ≥ 3 treatment-emergent adverse event (TEAE) was reported in 68.3% of patients. Neutropenia, hypertension, diarrhea, and asthenia were the most frequently occurring grade ≥ 3 TEAEs. Antivascular endothelial growth factor class events were infrequent. Subgroup analyses did not reveal major differences in the safety profile according to age, renal and hepatic status, race, or prior anticancer therapy. For the total population, median overall survival was 12.5 months, median progression-free survival was 6.1 months, and overall response rate was 16.3%. Aflibercept in combination with FOLFIRI is a safe and efficacious regimen administered in current clinical practice to patients with mCRC previously treated with oxaliplatin. The study results, conducted in real-world clinical practice with a less selected patient population, are aligned with the VELOUR (NCT00561470) trial and no new safety issues were identified.
Open AccessSafety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study
For patients with metastatic colorectal cancer (mCRC) that have failed a first-line oxaliplatin-based regimen, the preferred treatment option is an irinotecan-based regimen. This prospective, observational, noncomparative, post-authorization safety study (OZONE) evaluated the safety and effectiveness of aflibercept plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) in patients with mCRC treated in daily practice after failure of an oxaliplatin-based regimen. Patients were grouped by age, renal impairment, hepatic impairment, race, number, and type of prior anticancer therapy. Of 766 treated patients enrolled, 59.5% were male, 94.8% had an Eastern Cooperative Oncology Group performance status of 0–1, all received previous chemotherapy (97.8% including oxaliplatin), and 58.6% had prior exposure to bevacizumab. At least one grade ≥ 3 treatment-emergent adverse event (TEAE) was reported in 68.3% of patients. Neutropenia, hypertension, diarrhea, and asthenia were the most frequently occurring grade ≥ 3 TEAEs. Antivascular endothelial growth factor class events were infrequent. Subgroup analyses did not reveal major differences in the safety profile according to age, renal and hepatic status, race, or prior anticancer therapy. For the total population, median overall survival was 12.5 months, median progression-free survival was 6.1 months, and overall response rate was 16.3%. Aflibercept in combination with FOLFIRI is a safe and efficacious regimen administered in current clinical practice to patients with mCRC previously treated with oxaliplatin. The study results, conducted in real-world clinical practice with a less selected patient population, are aligned with the VELOUR (NCT00561470) trial and no new safety issues were identified.
- Open Access
- 1 May 2016
- Published by Solen s.r.o. in Onkologie
- Vol. 10 (2) , 80-86
Treatment of gastrointestinal stromal tumour
- 1 May 2016
- Published by Solen s.r.o. in Onkologie
- Vol. 10 (2) , 80-86
Open AccessTreatment of gastrointestinal stromal tumour